MOPP regimen
WikiDoc Resources for MOPP regimen |
Articles |
---|
Most recent articles on MOPP regimen Most cited articles on MOPP regimen |
Media |
Powerpoint slides on MOPP regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on MOPP regimen at Clinical Trials.gov Clinical Trials on MOPP regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on MOPP regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on MOPP regimen Discussion groups on MOPP regimen Patient Handouts on MOPP regimen Directions to Hospitals Treating MOPP regimen Risk calculators and risk factors for MOPP regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for MOPP regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords: Mechlorethamine/Prednisone/Procarbazine/Vincristine Regimen; MOPP; MOPP Regimen; MOPP regimen; Mustargen-Oncovin-Procarbazine-Prednisone Regimen; NM/PCB/PRED/VCR
Overview
MOPP regimen refers to a chemotherapy regimen consisting of mechlorethamine, vincristine (Oncovin), procarbazine and prednisone, used alone or in combination with radiation therapy for the treatment of stage I-IV Hodgkin lymphoma. Due to the increased risk of gonadal toxicity, this regimen has been widely replaced by the ABVD regimen.[1][2]
Regimen
MMechlorethamine
OVincristine (Oncovin)
PProcarbazine
PPrednisone
Indications
- Stage I-IV Hodgkin lymphoma[1][3]
References
- ↑ 1.0 1.1 Filatova LV, Plotnikova AA, Gershanovich ML, Semiglazova TIu (2013). "[Effectiveness and toxicity of MOPP, ABVD, BEACOPP chemotherapy in first-diagnosed Hodgkin lymphoma with a poor prognosis]". Vopr Onkol. 59 (2): 59–65. PMID 23814851.
- ↑ "NCI Thesaurus".
- ↑ "NCI Thesaurus".